Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison.
Schuster SJ, Zhang J, Yang H, Agarwal A, Tang W, Martinez-Prieto M, Bollu V, Kuzan D, Maziarz RT, Kersten MJ. Schuster SJ, et al. Among authors: bollu v. Leuk Lymphoma. 2022 Apr;63(4):845-854. doi: 10.1080/10428194.2021.2010069. Epub 2022 Jan 2. Leuk Lymphoma. 2022. PMID: 34978255 Free article.
Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States.
Maziarz RT, Yang H, Liu Q, Wang T, Zhao J, Lim S, Lee S, Dalal A, Bollu V. Maziarz RT, et al. Among authors: bollu v. Leuk Lymphoma. 2022 Sep;63(9):2052-2062. doi: 10.1080/10428194.2022.2060503. Epub 2022 Apr 14. Leuk Lymphoma. 2022. PMID: 35422192 Free article.
A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL).
Salles G, Schuster SJ, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith S, Jiménez-Ubieto A, Davis KL, Nagar S, Zhang J, Bollu V, Jousseaume E, Ramos R, Wang Y, Link BK. Salles G, et al. Among authors: bollu v. Hemasphere. 2022 Jun 21;6(7):e745. doi: 10.1097/HS9.0000000000000745. eCollection 2022 Jul. Hemasphere. 2022. PMID: 35813099 Free PMC article.
Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy - a retrospective cohort study using CMS 100% Medicare claims database.
Yang H, Bollu V, Lim S, Tesfaye M, Dalal AA, Lax A, Sethi S, Zhao J. Yang H, et al. Among authors: bollu v. Leuk Lymphoma. 2023 Feb;64(2):339-348. doi: 10.1080/10428194.2022.2147395. Epub 2022 Nov 21. Leuk Lymphoma. 2023. PMID: 36408973 Free article.
34 results